3Wolfenden LL, Diette GB, Krishnan JA, et al. Lower physician estimate of underlying asthma severity leads to undertreatment. Arch Intern Med, 2003,2:231. 被引量：1
4Price DB, Hemadez D, Magyar P, et al. Clinical Outcomes with Montelukast as a Partner Agent to Corticosteroid Therapy (COMPACT) International Study Group. Radomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax, 2003, 58:211. 被引量：1
5Vaquerizo MJ , Casan P, Castillo J , et al. CASIOPEA (Cap acid adde Singulair Oral en la Prevention de Exacerbaciones Asmaticas) Study Group. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax, 2003,58:204. 被引量：1
6David B. Corry emerging immune targets for the therapy of allergic asthma. Nature Reviews Drug Discovery,2002,1 :55. 被引量：1
7Nathan RA, Sorkness CA, Kosinski M, et al. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol, 2004,113 : 59. 被引量：1
8Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: Reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol,2006, 117:549. 被引量：1
4Bateman ED,Hurd SS,et al.Global strategy for asthma management and prevention:GINA executive sumnary[J].Eur Respir J,2008,31(1):143-178. 被引量：1
5Bateman ED,Boushey HA,Bousquet J,et al.Can guideline defined asthma control be achieved? The Gaining Optimal Asthma Control Study[J].Am J Respir Crit Care Med,2004,170(8):836-844. 被引量：1
